AAAAAA
Results:
1-9
|
Results: 9
Authors:
Stittelaar, KJ
Kuiken, T
de Swart, RL
van Amerongen, G
Vos, HW
Niesters, HGM
van Schalkwijk, P
van der Kwast, T
Wyatt, LS
Moss, B
Osterhaus, ADME
Citation: Kj. Stittelaar et al., Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques, VACCINE, 19(27), 2001, pp. 3700-3709
Authors:
Amara, RR
Villinger, F
Altman, JD
Lydy, SL
O'Neil, SP
Staprans, SI
Montefiori, DC
Xu, Y
Herndon, JG
Wyatt, LS
Candido, MA
Kozyr, NL
Earl, PL
Smith, JM
Ma, HL
Grimm, BD
Hulsey, ML
Miller, J
McClure, HM
McNicholl, JM
Moss, B
Robinson, HL
Citation: Rr. Amara et al., Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine, SCIENCE, 292(5514), 2001, pp. 69-74
Authors:
Barouch, DH
Craiu, A
Santra, S
Egan, MA
Schmitz, JE
Kuroda, MJ
Fu, TM
Nam, JH
Wyatt, LS
Lifton, MA
Krivulka, GR
Nickerson, CE
Lord, CI
Moss, B
Lewis, MG
Hirsch, VM
Shiver, JW
Letvin, NL
Citation: Dh. Barouch et al., Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys, J VIROLOGY, 75(5), 2001, pp. 2462-2467
Authors:
Barouch, DH
Santra, S
Kuroda, MJ
Schmitz, JE
Plishka, R
Buckler-White, A
Gaitan, AE
Zin, R
Nam, JH
Wyatt, LS
Lifton, MA
Nickerson, CE
Moss, B
Montefiori, DC
Hirsch, VM
Letvin, NL
Citation: Dh. Barouch et al., Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination, J VIROLOGY, 75(11), 2001, pp. 5151-5158
Authors:
Paz, K
Boura-Halfon, S
Wyatt, LS
LeRoith, D
Zick, Y
Citation: K. Paz et al., The juxtamembrane but not the carboxyl-terminal domain of the insulin receptor mediates insulin's metabolic functions in primary adipocytes and cultured hepatoma cells, J MOL ENDOC, 24(3), 2000, pp. 419-432
Authors:
Stittelaar, KJ
Wyatt, LS
de Swart, RL
Vos, HW
Groen, J
van Amerongen, G
van Binnendijk, RS
Rozenblatt, S
Moss, B
Osterhaus, ADME
Citation: Kj. Stittelaar et al., Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies, J VIROLOGY, 74(9), 2000, pp. 4236-4243
Authors:
Wyatt, LS
Whitehead, SS
Venanzi, KA
Murphy, BR
Moss, B
Citation: Ls. Wyatt et al., Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA, VACCINE, 18(5-6), 1999, pp. 392-397
Authors:
Nam, JH
Wyatt, LS
Chae, SL
Cho, HW
Park, YK
Moss, B
Citation: Jh. Nam et al., Protection against lethal Japanese encephalitis virus infection of mice byimmunization with the highly attenuated MVA strain of vaccinia virus expressing JEV prM and E genes, VACCINE, 17(3), 1999, pp. 261-268
Authors:
Durbin, AP
Cho, CJ
Elkins, WR
Wyatt, LS
Moss, B
Murphy, BR
Citation: Ap. Durbin et al., Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies, J INFEC DIS, 179(6), 1999, pp. 1345-1351
Risultati:
1-9
|